These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 33978625)

  • 1. Bevacizumab in Retinopathy of Prematurity : Concerns and adverse effects.
    Sharma A; Shetty A; Reddy YCVG
    Nepal J Ophthalmol; 2020 Jul; 12(24):298-307. PubMed ID: 33978625
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-vascular endothelial growth factor (VEGF) drugs for treatment of retinopathy of prematurity.
    Sankar MJ; Sankar J; Mehta M; Bhat V; Srinivasan R
    Cochrane Database Syst Rev; 2016; 2():CD009734. PubMed ID: 26932750
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Are we there yet? Bevacizumab therapy for retinopathy of prematurity.
    Darlow BA; Ells AL; Gilbert CE; Gole GA; Quinn GE
    Arch Dis Child Fetal Neonatal Ed; 2013 Mar; 98(2):F170-4. PubMed ID: 22209748
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reactivation of retinopathy of prematurity after ranibizumab treatment.
    Wong RK; Hubschman S; Tsui I
    Retina; 2015 Apr; 35(4):675-80. PubMed ID: 25768252
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-Vascular Endothelial Growth Factor Preparations in the Treatment of Retinopathy of Prematurity: Balancing Risks and Benefits.
    Chawla D; Darlow BA
    Indian Pediatr; 2016 Nov; 53 Suppl 2():S129-S136. PubMed ID: 27915321
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravitreal anti-VEGF therapy as a treatment for retinopathy of prematurity: what we know after 7 years.
    Klufas MA; Chan RV
    J Pediatr Ophthalmol Strabismus; 2015; 52(2):77-84. PubMed ID: 25798707
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bilateral Vitreous Hemorrhage Following Bilateral Intravitreal Injections of Bevacizumab in an Infant With Retinopathy of Prematurity.
    Theophanous C; Schechet S; Rodriguez SH; Blair M
    Ophthalmic Surg Lasers Imaging Retina; 2018 Nov; 49(11):893-896. PubMed ID: 30457649
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of intravitreal bevacizumab for zone-II retinopathy of prematurity.
    Karkhaneh R; Khodabande A; Riazi-Eafahani M; Roohipoor R; Ghassemi F; Imani M; Dastjani Farahani A; Ebrahimi Adib N; Torabi H
    Acta Ophthalmol; 2016 Sep; 94(6):e417-20. PubMed ID: 27009449
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravitreal bevacizumab injection in aggressive posterior retinopathy of prematurity compared with type I retinopathy of prematurity.
    Eftekhari Milani A; Hassanpoor N; Mousavi Mirkala M; Taheri A; Golizade A; Niyousha MR
    Int Ophthalmol; 2020 Feb; 40(2):477-482. PubMed ID: 31712928
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy comparison of anti-vascular endothelial growth factor drugs for the treatment of type 1 retinopathy of prematurity: A network meta-analysis of randomised controlled trials.
    Zhou M; Hashimoto K; Liu W; Cai Y; Liang J; Shi X; Zhao M
    Graefes Arch Clin Exp Ophthalmol; 2024 May; 262(5):1409-1419. PubMed ID: 37815595
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Off-label use of intravitreal bevacizumab for severe retinopathy of prematurity].
    Alba LE; Zaldua RA; Masini RA
    Arch Soc Esp Oftalmol; 2015 Feb; 90(2):81-6. PubMed ID: 25459682
    [TBL] [Abstract][Full Text] [Related]  

  • 12. On safety, pharmacokinetics and dosage of bevacizumab in ROP treatment - a review.
    Hård AL; Hellström A
    Acta Paediatr; 2011 Dec; 100(12):1523-7. PubMed ID: 21854449
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum levels of vascular endothelial growth factor and related factors after intravitreous bevacizumab injection for retinopathy of prematurity.
    Wu WC; Lien R; Liao PJ; Wang NK; Chen YP; Chao AN; Chen KJ; Chen TL; Hwang YS; Lai CC
    JAMA Ophthalmol; 2015 Apr; 133(4):391-7. PubMed ID: 25569026
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypotension Associated With Intravitreal Bevacizumab Therapy for Retinopathy of Prematurity.
    Wu LH; Yang YH; Lin CH; Lin YJ; Cheng CL
    Pediatrics; 2016 Feb; 137(2):e20152005. PubMed ID: 26743817
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Description and management of retinopathy of prematurity reactivation after intravitreal antivascular endothelial growth factor therapy.
    Valikodath NG; Chiang MF; Chan RVP
    Curr Opin Ophthalmol; 2021 Sep; 32(5):468-474. PubMed ID: 34397577
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects and complications of bevacizumab use in patients with retinopathy of prematurity: a multicenter study in taiwan.
    Wu WC; Yeh PT; Chen SN; Yang CM; Lai CC; Kuo HK
    Ophthalmology; 2011 Jan; 118(1):176-83. PubMed ID: 20673589
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravitreal Bevacizumab for Zone II Retinopathy of Prematurity.
    Larrañaga-Fragoso P; Peralta J; Bravo-Ljubetic L; Pastora N; Abelairas-Gómez J
    J Pediatr Ophthalmol Strabismus; 2016 Nov; 53(6):375-382. PubMed ID: 27537247
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antivascular endothelial growth factor in the treatment of retinopathy of prematurity.
    Patel JR; Ranjan SS; Wasserman BN
    Curr Opin Ophthalmol; 2016 Sep; 27(5):387-92. PubMed ID: 27206263
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravitreal bevacizumab monotherapy for type-1 prethreshold, threshold, and aggressive posterior retinopathy of prematurity - 27 month follow-up results from Turkey.
    Yetik H; Gunay M; Sirop S; Salihoglu Z
    Graefes Arch Clin Exp Ophthalmol; 2015 Oct; 253(10):1677-83. PubMed ID: 25501298
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Very Late Reactivation of Retinopathy of Prematurity After Monotherapy With Intravitreal Bevacizumab.
    Snyder LL; Garcia-Gonzalez JM; Shapiro MJ; Blair MP
    Ophthalmic Surg Lasers Imaging Retina; 2016 Mar; 47(3):280-3. PubMed ID: 26985803
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.